Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Elranatamab in Multiple Myeloma: NCT06988488 Clinical Landscape Report 2026
15 October 2026
NCT06988488 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti CD19 chimeric antigen receptor T cell therapy(Beijing Boren Hospital) in Idiopathic Inflammatory Myopathies: NCT06993493 Clinical Landscape Report 2026
15 October 2026
NCT06993493 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Gilteritinib Fumarate in Acute Myeloid Leukemia: NCT06992934 Clinical Landscape Report 2026
15 October 2026
NCT06992934 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dabogratinib in Non-Muscle Invasive Bladder Neoplasms: NCT06995677 Clinical Landscape Report 2026
15 October 2026
NCT06995677 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
CBX-250 in Acute Myeloid Leukemia: NCT06994676 Clinical Landscape Report 2026
15 October 2026
NCT06994676 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QLS4131 in Systemic Lupus Erythematosus: NCT07001839 Clinical Landscape Report 2026
15 October 2026
NCT07001839 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Talquetamab in Multiple Myeloma: NCT06993675 Clinical Landscape Report 2026
15 October 2026
NCT06993675 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in Recurrent Bladder Cancer: NCT07000084 Clinical Landscape Report 2026
15 October 2026
NCT07000084 clinical landscape for Recurrent Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daratumumab in Multiple Myeloma: CTRI/2025/05/087866 Clinical Landscape Report 2026
15 October 2026
CTRI/2025/05/087866 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Multiple Myeloma: NCT06997081 Clinical Landscape Report 2026
15 October 2026
NCT06997081 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Acute Myeloid Leukemia: NCT06996119 Clinical Landscape Report 2026
15 October 2026
NCT06996119 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti BCAM CAR-T Cell(The First Affiliated Hospital of Nanchang University) in Multiple Myeloma: NCT06999031 Clinical Landscape Report 2026
15 October 2026
NCT06999031 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.